Wells Fargo & Company Regulus Therapeutics Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 35,159 shares of RGLS stock, worth $42,542. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,159
Previous 26,585
32.25%
Holding current value
$42,542
Previous $41,000
34.15%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding RGLS
# of Institutions
75Shares Held
53.3MCall Options Held
42.9KPut Options Held
9.3K-
Federated Hermes, Inc. Pittsburgh, PA12.9MShares$15.6 Million0.05% of portfolio
-
Nea Management Company, LLC Timonium, MD6.47MShares$7.83 Million0.73% of portfolio
-
Vivo Capital, LLC Palo Alto, CA5MShares$6.05 Million1.54% of portfolio
-
Octagon Capital Advisors LP New York, NY4.85MShares$5.87 Million1.71% of portfolio
-
Black Rock Inc. New York, NY3.97MShares$4.8 Million0.0% of portfolio
About Regulus Therapeutics Inc.
- Ticker RGLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,634,400
- Market Cap $17.7M
- Description
- Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...